Literature DB >> 2186632

Control of renal function during intrarenal infusion of endothelin.

D L Stacy1, J W Scott, J P Granger.   

Abstract

It has been demonstrated that bolus injections of a vasoconstrictor derived from endothelial cells, endothelin 1 (ET-1), constricts isolated arteries and increases blood pressure in animals when infused intravenously. The purpose of this study was to examine the direct effects of intrarenal infusions of ET-1 on renal function at doses that do not alter systemic arterial pressure. The effects of ET-1 on renal hemodynamics and electrolyte excretion were examined during 40 min of intrarenal infusions of ET-1 at rates of 1.15 and 5 ng.kg-1.min-1. Infusion of ET-1 (1.15 ng.kg-1.min-1) resulted in a transient increase in renal blood flow (RBF) followed by a progressive vasoconstriction, which reduced RBF by 23%. ET-1 decreased glomerular filtration rate (GFR) and had no significant effect on filtration fraction. Intrarenal infusion of ET-1 (1.15 ng.kg-1.min-1) had no effect on fractional excretion of sodium (FENa) or potassium. Infusion of ET-1 at a higher dose (5 ng.kg-1.min-1) produced further reductions in RBF, GFR, and FENa. These data indicate that ET-1 is a potent renal vasoconstrictor that could play a role in controlling renal hemodynamics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2186632     DOI: 10.1152/ajprenal.1990.258.5.F1232

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  3 in total

Review 1.  Bosentan and the endothelin system in congestive heart failure.

Authors:  S H Ellahham; V Charlon; Z Abassi; K A Calis; W K Choucair
Journal:  Clin Cardiol       Date:  2000-11       Impact factor: 2.882

Review 2.  Role of endothelin in hypertension.

Authors:  B K Krämer; M Ackermann; S M Kohler; G A Riegger
Journal:  Clin Investig       Date:  1994-01

3.  Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats.

Authors:  E L Schiffrin; P Sventek; J S Li; A Turgeon; T Reudelhuber
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.